MOLURACE
MRP: 2,600
Packaging: 10x4
Pack Type: capsule
Composition:
Molnupiravir 200mg
Indication:
Combat OMICRON Wave SARS-CoV-2
Description:
Molnupiravir 200 mg is an oral antiviral medication developed to treat mild to moderate COVID-19 in adults at risk of progressing to severe illness. It is a prodrug of the ribonucleoside analog N4-hydroxycytidine (NHC), which works by introducing errors into the viral RNA during replication, ultimately preventing the virus from multiplying.
Molnupiravir is most effective when initiated within 5 days of symptom onset, and it has shown efficacy in reducing hospitalization and death in high-risk COVID-19 patients. It is not a substitute for vaccination, but a treatment option for breakthrough or unvaccinated infections.
Tags:
- Reduces risk of hospitalization and death in high-risk COVID patients
- Oral dosage – no IV or hospital administration required
- Convenient 5-day course
- Active against SARS-CoV-2 viral replication
- Well tolerated in most adults
Usage Information
Dosage
Adults: 800 mg (i.e., four 200 mg capsules) every 12 hours for 5 days Swallow whole with water; do not crush or chew Start within 5 days of COVID-19 symptom onset Do not exceed 5 days of therapy Always follow your physician's prescribed instructions.
Side Effects
Diarrhea Nausea Dizziness Headache Rare: Allergic reactions or mild skin rash
Contraindications
Pregnancy – Contraindicated due to potential teratogenicity Breastfeeding – Not recommended Children under 18 years – Safety and efficacy not established Hypersensitivity to Molnupiravir or any excipients
Availability
Molnupiravir 200 mg capsule COVID-19 antiviral treatment Oral COVID medication Molnupiravir dosage and usage Antiviral for coronavirus Molnupiravir side effects Emergency COVID treatment SARS-CoV-2 treatment tablet Buy Molnupiravir online FDA approved COVID treatment